Forbion announces first close of its new BioEconomy Fund I: backing biotech-enabled companies aiming to impact the future of our planet
June 20, 2024 01:25 ET
|
Forbion
Forbion announces the first close of its latest fund, Forbion BioEconomy Fund I (“Forbion BioEconomy"), at €75 million.
Forbion co-leads €129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023
November 13, 2023 09:55 ET
|
Forbion
Successful fundraising demonstrates value of Forbion platform, with multiple Forbion fund strategies supporting VectorY’s development since launch
Forbion co-leads $175 million Series B financing of Mariana Oncology as first investment of Forbion Ventures Fund VI
September 07, 2023 06:45 ET
|
Forbion
Forbion co-leads oversubscribed Series B financing in next-generation radiopharmaceuticals companyFirst investment by its Forbion Ventures Fund VI, aimed at advancing highly impactful...
enGene, Inc. and Forbion European Acquisition Corp. (“FEAC”, Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies
May 17, 2023 07:00 ET
|
Forbion
Leading institutional investors commit $135 million USD in transaction financing, anchored by FEAC’s sponsor, Forbion Growth Sponsor FEAC I B.V. (together with its parent entity Forbion Growth...
Forbion appoints Silva Deželan, PhD as Head of Impact and ESG
May 04, 2023 08:59 ET
|
Forbion
NAARDEN, Netherlands and MUNICH, Germany, May 04, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, announces the appointment of Silva Deželan PhD, as...
Forbion raises €1.35 billion across two funds
April 19, 2023 01:00 ET
|
Forbion
Forbion’s largest fundraising to date€750 million raised in the final close of the Forbion Ventures Fund VI €600 million raised in the final close of the Forbion Growth Opportunities Fund II Brings...
Forbion Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofim
August 04, 2022 03:00 ET
|
Forbion
Forbion Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofim Naarden, The Netherlands, 4 August 2022 – Forbion, a leading European life...
Forbion appoints Dr. Peter Høngaard Andersen as Operating Partner and Dr. Matt Cooper as Venture Partner
July 20, 2022 02:00 ET
|
Forbion
Forbion appoints Dr. Peter Høngaard Andersen as Operating Partner and Dr. Matt Cooper as Venture Partner Naarden, The Netherlands – 20 July 2022 – Forbion, a leading European life sciences venture...
Forbion announces first close of Forbion Growth Opportunities Fund II at €470 million
June 09, 2022 02:00 ET
|
Forbion
Forbion announces first close of Forbion Growth Opportunities Fund II at €470 million New fund to invest in late-stage European life sciences companiesInvestors include Pantheon, pension funds PME...
BGV Expands Team with the Appointment of a Partner and Venture Partner
September 14, 2021 02:00 ET
|
BioGeneration Ventures
BGV Expands Team with the Appointment of a Partner and Venture Partner Naarden, The Netherlands, 14 September 2021 – BioGeneration Ventures (“BGV”), a leading early-stage VC in European biopharma,...